Highly effective drugs that can cure chronic hepatitis C infection in approximately 95 percent of patients first became available in the U.S. in 2014. But both public and private insurers continue to deny coverage for these costly drugs at high rates nationwide, despite efforts to remove treatment restrictions, according to a new study published in Open Forum Infectious Diseases. The […]

Continue reading »